Immunex Corporation and Genentech, Inc. join forces to develop TRAIL/Apo2L in cancer

June 01, 1999

SEATTLE and SOUTH SAN FRANCISCO, June 1, 1999- Immunex Corporation (NASDAQ: IMNX) and Genentech, Inc. (NYSE:GNE) announced today that the two companies agreed to jointly develop TRAIL/Apo2L, an entirely new approach to research in the fight against cancer. Pending FDA approval, the companies have also agreed to jointly commercialize the product.

"Combining our world class leadership in science and pharmaceutical development enhances our ability to more efficiently evaluate TRAIL/Apo2L and its potential to fight cancer," said Arthur D. Levinson, PhD, Genentech president and CEO, and Ed Fritzky, Immunex chairman and CEO, in a joint statement. "Should the science and clinical studies prove consistent with the preclinical findings that the molecule has already shown, our companies are poised to move to the next level of development with this new technology."

Immunex and Genentech have each conducted extensive preclinical testing of different forms of TRAIL/Apo2L. TRAIL/Apo2L, also known as TNF-related apoptosis-inducing ligand, appears in animal models to suppress tumor growth and causes remission of tumors, by a direct and specific mechanism known as apoptosis, or programmed cell death. TRAIL/Apo2L binds to at least four distinct receptors found on many tumor cells and signals these cells to destroy themselves through apoptosis. In preclinical research, TRAIL/Apo2L has been shown to cause a wide variety of tumor cells to undergo apoptosis while sparing normal cells. Preclinical studies have not identified significant toxicities from TRAIL/Apo2L administration.

The companies will form a joint steering committee and project team to select a single lead molecule for development, manage the development process, and allocate clinical, manufacturing and marketing responsibilities to each company. Immunex and Genentech each have filed patent applications covering TRAIL/Apo2L and its uses, and Immunex was awarded a patent covering the TRAIL gene in June 1998. Under the terms of the collaboration agreement, the companies will share all development and commercialization costs. The companies will co-promote TRAIL/Apo2L worldwide using the oncology sales forces of both companies. Profits from the worldwide sales of the product will be shared.

Immunex Corporation is a biopharmaceutical company dedicated to developing immune system science to protect human health. The company's products offer hope to patients with cancer, inflammatory and infectious diseases.

American Home Products owns a majority interest in Immunex. AHP is one of the world's largest research-based pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of prescription drugs and over-the-counter medications. It is also a leader in vaccines, biotechnology, agricultural products, and animal health care.

Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. Twelve of the currently marketed biotechnology products stem from Genentech science. Genentech markets seven biotechnology products directly in the United States. The company has headquarters in South San Francisco, California, and is traded on the New York Stock Exchange and the Pacific Exchange under the symbol GNE.
NOTE: This news release contains forward-looking statements with respect to Immunex that involve risks and uncertainties, including risks associated with clinical development, regulatory approvals, patent litigation, product commercialization, and other risks described from time to time in the SEC reports filed by Immunex, including the most recently filed form 10-K and form 10-Q. For more information, please refer to

An electronic version of this news release - as well as additional information about Immunex of interest to investors, customers, future employees and patients - is available on the Immunex home page at

Media Contacts:

Paul Laland
Genentech Inc.

Investor Contacts:

Mark Leahy
Immunex Corp.

Susan Bentley
Genentech Inc.

Immunex Corporation

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to